Third, co-treatment with SAR7334 and MCC950 in vitro showed a slight trend toward further reduction of fibrosis-related and NLRP3 pathway markers, but the difference did not reach statistical significance.
← all excerpts
TRPC6 Inhibition Attenuates Renal Tubulointerstitial Fibrosis via the Reactive Oxygen Species/TXNIP/NLRP3 Signaling Pathway.
1
—
—